DC Field | Value | Language |
---|---|---|
dc.contributor.author | Y I Chung | - |
dc.contributor.author | S K Kim | - |
dc.contributor.author | Y K Lee | - |
dc.contributor.author | Su-Jin Park | - |
dc.contributor.author | K O Cho | - |
dc.contributor.author | S H Yuk | - |
dc.contributor.author | G Tae | - |
dc.contributor.author | Y H Kim | - |
dc.date.accessioned | 2017-04-19T09:18:25Z | - |
dc.date.available | 2017-04-19T09:18:25Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | 10.1016/j.jconrel.2010.01.010 | ko |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/9503 | - |
dc.description.abstract | We investigated the angiogenic bioactivity and therapeutic angiogenic effect of vascular endothelial growth factor (VEGF) administration by the heparin-functionalized nanoparticle-fibrin gel complex. The markedly increased bioactivity was observed by the VEGF-loaded nanoparticle-fibrin gel complex, compared to the VEGF-loaded fibrin gel, the nanoparticle-fibrin gel complex without VEGF, or fibrin gel (control) in terms of the capillary density in a mouse subcutaneous implantation model. Furthermore, the VEGF-loaded nanoparticle-fibrin gel complex significantly enhanced the therapeutic angiogenic effect in a rabbit ischemic hind limb model: the noticeable increase in the recovered calf blood pressure, the angiographic score, and the density of collaterals, as well as the stable maintenance of the organized collaterals, compared to the VEGF-loaded fibrin gel. These results show the enhanced angiogenic potential of VEGF administration by the proposed heparin-functionalized nanoparticle-fibrin gel complex. | - |
dc.publisher | Elsevier | - |
dc.title | Efficient revascularization by VEGF administration via heparin-functionalized nanoparticle-fibrin complex | - |
dc.title.alternative | Efficient revascularization by VEGF administration via heparin-functionalized nanoparticle-fibrin complex | - |
dc.type | Article | - |
dc.citation.title | Journal of Controlled Release | - |
dc.citation.number | 3 | - |
dc.citation.endPage | 289 | - |
dc.citation.startPage | 282 | - |
dc.citation.volume | 143 | - |
dc.contributor.affiliatedAuthor | Su-Jin Park | - |
dc.contributor.alternativeName | 정용일 | - |
dc.contributor.alternativeName | 김상기 | - |
dc.contributor.alternativeName | 이윤경 | - |
dc.contributor.alternativeName | 박수진 | - |
dc.contributor.alternativeName | 조경오 | - |
dc.contributor.alternativeName | 육순홍 | - |
dc.contributor.alternativeName | 태기융 | - |
dc.contributor.alternativeName | 김영하 | - |
dc.identifier.bibliographicCitation | Journal of Controlled Release, vol. 143, no. 3, pp. 282-289 | - |
dc.identifier.doi | 10.1016/j.jconrel.2010.01.010 | - |
dc.subject.keyword | Angiogenesis | - |
dc.subject.keyword | Controlled release | - |
dc.subject.keyword | Fibrin | - |
dc.subject.keyword | Growth factors | - |
dc.subject.keyword | Heparin | - |
dc.subject.local | Angiogenesis | - |
dc.subject.local | angiogenesis | - |
dc.subject.local | controlled release | - |
dc.subject.local | Controlled release | - |
dc.subject.local | Fibrin | - |
dc.subject.local | fibrin | - |
dc.subject.local | growth factor | - |
dc.subject.local | Growth Factor | - |
dc.subject.local | Growth factors | - |
dc.subject.local | Growth factor | - |
dc.subject.local | Heparin | - |
dc.description.journalClass | Y | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.